| 27.98 0.47 (1.71%) | 06-04 11:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.22 | 1-year : | 34.68 |
| Resists | First : | 28.44 | Second : | 29.7 |
| Pivot price | 27.52 |
|||
| Supports | First : | 26.42 | Second : | 21.98 |
| MAs | MA(5) : | 27.72 |
MA(20) : | 27.6 |
| MA(100) : | 30.93 |
MA(250) : | 31.41 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 50.1 |
D(3) : | 48.3 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 37.77 | Low : | 26.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GLPG ] has closed below upper band by 26.5%. Bollinger Bands are 16.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.12 - 28.22 | 28.22 - 28.35 |
| Low: | 27.2 - 27.32 | 27.32 - 27.46 |
| Close: | 27.76 - 27.95 | 27.95 - 28.17 |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Thu, 21 May 2026
GLPG SEC Filings - Galapagos Nv 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 08 May 2026
LKFT Stock Price and Chart — EURONEXT:LKFT - TradingView
Thu, 07 May 2026
GLPG.AS Technical Analysis | Trend, Signals & Chart Patterns | GALAPAGOS NV (AMS:GLPG) - ChartMill
Wed, 06 May 2026
Galapagos (GLPG) posts Q1 2026 profit and commits up to €790M to Ouro deal - Stock Titan
Thu, 30 Apr 2026
Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul - The Globe and Mail
Fri, 24 Apr 2026
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 22.3 (%) |
| Shares Short | 1,370 (K) |
| Shares Short P.Month | 911 (K) |
| EPS | 8.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.9 |
| Profit Margin | 46.8 % |
| Operating Margin | -983 % |
| Return on Assets (ttm) | 10.6 % |
| Return on Equity (ttm) | 16.2 % |
| Qtrly Rev. Growth | -91.5 % |
| Gross Profit (p.s.) | 8.55 |
| Sales Per Share | 15.78 |
| EBITDA (p.s.) | 10.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -302 (M) |
| Levered Free Cash Flow | 211 (M) |
| PE Ratio | 3.21 |
| PEG Ratio | 0 |
| Price to Book value | 9.64 |
| Price to Sales | 1.77 |
| Price to Cash Flow | -6.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|